Magrolimab is an anti-CD47

'Gilead Sciences, Inc. today announced it has discontinued the Phase 3 ENHANCE-3 study of magrolimab in AML and that the (FDA) placed all magrolimab studies in myelodysplastic syndromes and AML, including related expanded access programs, on full clinical hold'
#Leukemia #ClinicalTrial #CD47 #Hematology

https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-discontinuation-of-phase-3-enhance-3-study-in-aml